WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND
|
|
- Madeleine Watts
- 6 years ago
- Views:
Transcription
1 SOP Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central Fax central WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General information Name of Manufacturer Unit number Production Block Mylan Laboratories Limited Mylan Nashik ( Sinnar in CRM) NA Physical address F-4, F-12, Malegaon M.I.D.C, Sinnar, Nashik , Maharashtra state, India Contact personand address. Mr. Pallab De, Sr. Vice-President and Quality Head- OSD Operations, Corporate Quality Assurance, Mylan Laboratories Limited, Plot no. 564 / A / 22, Road no. 92, Jubilee Hills, Hyderabad , India. Tel: , Fax: Mobile: , Pallab.De@mylan.in AND Date of inspection 9, 10, 11, 12 June 2015 Type of inspection Dosage forms(s) included in the inspection WHO product categories covered by the inspection Summary of the activities performed by the manufacturer Mr. Uday Kasbekar, Vice-President Manufacturing Operations, Mylan Laboratories Limited F-4, F-12, Malegaon M.I.D.C, Sinnar, Nashik , Maharashtra state, India, Direct: Mobile: uday.kasbekar@mylan.in Routine Immediate and delayed release tablets and hard gelatin capsules HA, MA and TB products Production, packaging, quality control testing and release of finished pharmaceutical products. 1 of 8
2 PART 2: SUMMARY General information about the company and site Globally, Mylan employed approximately 20,000 people. The manufacturing capacity was 45 billion dosage units. Approximately 12,000 employees were located in India. A total of 1811 employees were at the facility under inspection. The total plot area was 89,500 square meters, with approximately 22 acres of land. A neighbouring plot contained a supplementary finished product storage warehouse. A new warehouse was also under construction on the main plot of land. Production had the capacity to manufacture 6.5 billion tablets and capsules per year on a three shift basis. History of WHO and/or regulatory agency inspections This was the fifth inspection by WHO-PQ: the first was in July 2007, followed by inspections in July 2008 and August 2009 (special: data verification), then in June According to the company presentation, the site was also previously inspected by several stringent authorities over the last few years. According to the company presentation and site master file, the site had a total of 1,811 employees as of 9 th June 2015 distributed as: 1. Production Quality unit (QA, QC, Stability): Warehouse Engineering Process and Packaging Development Regulatory Affairs Others (Administration, Purchase, Accounts & Information Systems) 129 The inspection focused on the production and control of anti-hiv, anti-tb and antimalarial products. The inspection covered all the sections of the WHO GMP text, including premises, equipment, documentation, materials, validation, sanitation and hygiene, production, quality control and utilities. Inspected Areas Quality Assurance Sanitization and hygiene Qualification and validation Complaints Recalls Self-inspection Personnel Training Personal hygiene Premises Equipment Materials Documentation Production Quality control 2 of 8
3 PART 3: INSPECTION OUTCOME 3.1 PHARMACEUTICAL QUALITY SYSTEM (PQS) Quality risk management The standard operating procedure (SOP) for quality risk management effective from 09 June 2015, was reviewed and risk priority number was evaluated from severity of the impact, probability of occurrence and detection. The risk assessment manual dated 08 June 2015, was reviewed and functional risk identification was made in quality assurance (QA), Solid Dosage, Warehouse, Engineering, quality control (QC), Personnel and Administration and Process development. The system was well established and satisfactory overall. Product quality review The current version of the annual product quality review SOP was reviewed on the first day, along with annual product quality reviews for selected products. This area was considered satisfactory. Out-of-specifications (OOSs) These were maintained through Trackwise. OOSs were reviewed on the first day from the actual electronic records, as these represent the true recordings, rather than the paper data. There were 168 OOS s (opened and closed) listed for the entire site from January This was considered to be normal occurrence given the large amount of products manufactured at the site. Several examples were reviewed in detail. This area was considered acceptable overall. 3.2 GOOD MANUFACTURING PRACTICES (GMPs) FOR PHARMACEUTICAL PRODUCTS All manufacturing processes were clearly defined, systematically reviewed for associated risks in the light of scientific knowledge and experience, and shown to be capable of consistently manufacturing pharmaceutical products of the required quality that comply with their specifications. Qualification and validation are performed; All necessary resources were provided. 3.3 SANITATION AND HYGIENE The site had adequate procedures for sanitation and hygiene. This area was considered acceptable overall. 3.4 QUALIFICATION AND VALIDATION Validation Master Plan (VMP) The Validation Master Plan, approved 8 June 2015, was reviewed. Validation and qualification were guided by approved protocols. The schedules and frequencies for executed and planned requalification, validation and revalidation were outlined in annexes to the VMP. This area was considered acceptable after CAPAs. Process validation (PV) Selected exampled were reviewed. No observations were made. 3 of 8
4 Equipment qualification Qualification included User Requirements Specification (URS), Design Qualification (DQ), Factory Acceptance Tests (FAT), Installation Qualification (IQ), Operation Qualification (OQ) and Performance qualification (PQ). Computerized systems Caliber LIMS was the system in use and was initiated in January The server capacity was further enhanced in The documentation relating to the rollout of LIMS was reviewed. System design qualification, dated from 6 November 2013, was reviewed; this was a general overarching document. The sample information is manually entered in LIMS by the quality control user. The analyst entered the analytical observation manually, LIMS calculates the results and generated the certificates of analyses. Goods receipt was done in SAP. An inspection lot was generated in SAP. This goods receipt is done for a raw material, and packing material. Batch release is done in SAP through the inspection lot (which automatically generated by SAP). This inspection lot was manually fed into LIMS. There, LIMS generated an AR Number, which was associated to the multiple tests conducted for a particular lot. Once the certificate of analysis is generated and the LIMS process is completed. Then, the inspection lot is manually released in SAP. Quarantine status, in SAP, was identified as quality inspection. When a lot was released, in SAP it was identified as unrestricted. Any lot that was in an unrestricted status could be processed for further stages of execution. The company was still in the strategy alignment phase when it comes to fully integrating SAP with LIMS. The qualification of the ability of LIMS to calculate test results, was reviewed. A script was used to execute the test. The expected value was verified against the expected value. The tool used was camera enabled and took screen shots of each step. The validation of calculations for analytical reports, was done in the Test Environment. Electronic signatures were used. The tool formulas were verified each and every time at the time of master creation. The master formulas are registered under the test types. The person who is entering the variables into the master formula, has verified the results with the calculator. The ability of LIMS to record OOS results and investigations was verified by the inspector randomly picking and example, and verifying it against information earlier recorded from the Trackwise system for OOSs. 3.5 COMPLAINTS Handling of complaints SOP Version 7.0 effective as of 03 Sep. 2014, was reviewed. This SOP described the recording of the complaint the categorization of the complaint as critical, major or minor. This area was acceptable overall. 3.6 PRODUCT RECALLS Product recall and withdrawal SOP MLLNSK-SOP-QA-GMP-0021 Version 5.0 effective as of 10 Nov. 2013, was reviewed. There were 4 classes for recalls, class I (within 3 days), class II (within 7 days) and class III (within 15 days), mock recalls were performed on a yearly basis. This area was acceptable overall. 4 of 8
5 3.7 CONTRACT PRODUCTION AND ANALYSIS The SOP on the approval and evaluation of outside testing laboratories, Version 3.0, was reviewed. Amongst approved outside labs, four of them were Mylan groups. Vimta laboratories and Analytical solutions were third party laboratories. 3.8 SELF INSPECTION AND QUALITY AUDIT This area was generally considered acceptable. 3.9 PERSONNEL This area was generally considered acceptable TRAINING Training was being managed through the My university electronic system, which had just recently been fully implemented. There were 1835 total records, which matched the total number of employees reported to be employed at the site during the opening meeting. According to the system, there were 258 employees in quality control. One of the senior chemists, was selected as an example. He had been trained on HPLC operation and calibration for the pump, on waters equipment, on GLPs on safety, and on operation and calibration of dissolution testing apparatus. A paper-based training matrix was used. The scheduled date of training was set and was respected. A number of employees were marked as resigned. Training records were reviewed and considered acceptable PERSONAL HYGIENE The various changing areas inspected were clean, gowns used by personnel, were clean and free of product residue. There were no visible instructions on how to perform proper hand sanitization with isopropyl alcohol PREMISES General Premises were generally in an excellent state of maintenance and control. Ancillary areas These were satisfactory overall. Enough space was allocated for all of the required activities. Storage areas The finished product s offsite warehouse was inspected. It contained a large number of anti-arv products, most of them manufactured in May Weighing areas Weighing areas were generally acceptable. Production areas Production areas were generally acceptable. 5 of 8
6 Quality control areas Spacious, temperature/humidity controlled and adequately maintained premises were provided for all of the quality control activities performed at the facility EQUIPMENT An example of a rapid mixer granulator used in the manufacturing of the LNZ product, was seen to have heavily scratched surfaces. Most of the equipment seen in production, was nevertheless in an acceptable state of maintenance MATERIALS A SAP system was used to manage materials electronically. SAP showed a place called Interim Goods. In the example of Batch , it was stored in the finished goods antiretroviral store. The system showed that only retention samples were left (fourteen of them). Starting materials and packaging materials were received following acceptable procedures. Intermediate and bulk products were kept within the appropriate environmental conditions and within their approved hold periods. A validity period of 15 days was assigned to working standards these were clearly labelled. Those seen stored at 2-8 o C were in boxes with desiccant. Many resolution solutions were seen in the refrigerator. The laboratory would run stability tests on these to verify that their use was acceptable DOCUMENTATION The electronic documentation systems of Mylan Corporate were used for management of SOPs and of other documents at the site. This was done through a database called Documentum (version 5.0), that had been in use since June SOPs were routed for approval through this software. Once approved, the SOPs were still nevertheless implemented and distributed as a paper based system at the Mylan Nashik site, since the full electronic system has not yet been implemented at Nashik. SOPs have a new format compared to previous inspections, with includes version number, validity period at corporate, validity period at the Nashik site (three years, vs. 24 hours only at corporate/ Mainland sites), as well as the list of changes GOOD PRACTICES IN PRODUCTION Prevention of cross-contamination and bacterial contamination during production There were provisions in place to regularly clean the production equipment and premises (floors, ceilings, etc.). Dust extraction systems were in place to prevent accumulation of dust resulting from the various production activities (sifting, sieving, compression).. The controls in place were generally considered rigorous. Processing operations Processing operations were adequately performed. Only one product was manufactured in each room at any one time. 6 of 8
7 Packaging operations Primary packaging operations were inspected in process for the filling of bottles. Modern, state-of-the-art equipment was in place with controls for tablet count, bottle weight, labelling and metal contamination (this was tested in front of inspectors). Only 1 product and batch was packaged in a primary packaging room at one time and adequate procedures for line clearance were in place GOOD PRACTICES IN QUALITY CONTROL The quality control department was divided into two laboratories. The stability laboratory was equipped with 87 HPLC systems, and all of them were visible on the network. These systems were controlled using Empower 2. The release testing laboratory contained approximately 63 HPLCs and 11 GCs. All instruments were networked. On Day two, product lots found in the various warehouses at the site were verified against their status and test results in LIMS. It was noted that for the LNZ product, the specifications used specified dissolution test conditions of NLT 75% Q should be dissolved in 45 minutes for the three active ingredients that it contained. On Day three, the quality control stability laboratory was inspected. This laboratory was also used to perform comparative dissolution profiles. Analytical reports were generally detailed and were found to be filled contemporaneously during the inspection. Several reports were randomly selected and reviewed. For instance, the Niacin extended release tablets 750 mg dissolution profile was seen to be under way for the third commercial validation batch (batch No ) at the coating stage for the US market. Samples were taken through automated sampling equipment on a Lab India DS vessel dissolution testing apparatus. The nine hour dissolution sample time-point was witnessed by the inspector. The samples from the subsequent time-points would be taken in test tubes until 24 hours would be reached. The process validation protocol, clearly stated that dissolution profiles time-points should be 1, 2, 3, 4, 6, 9, 12, 15, 20 and 24 hours. With limits of NMT 20% for 1 hour, NLT 25% and NMT 50% for 6 hours, NLT 45% and NMT 75% for 12 hours and NLT 80% for 24 hours for coated tablets with immediate filtration. The calibration records showed that the sample volume taken was within ± 5% of the set volume for sample volume values of 5 ml, 10 ml and 10 ml (replenishment volume calibration). A few other dissolution test results and their procedures were reviewed by inspectors. 7 of 8
8 PART 4: CONCLUSION Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, as well as the corrective actions taken and planned, Mylan Nashik, F-4, F-12, Malegaon M.I.D.C, Sinnar, Nashik , Maharashtra state, India was considered to be operating at an acceptable level of compliance with WHO GMP guidelines. All the non-compliances observed during the inspection that were listed in the full report as well as those reflected in the WHOPIR, were addressed by the manufacturer, to a satisfactory level, prior to the publication of the WHOPIR. This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive. 8 of 8
Prequalification of Medicines Programme
Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General
More informationPrequalification of Medicines Programme
Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General
More informationPrequalification Team Inspection services WHO INSPECTION REPORT of the FPP manufacturer
Prequalification Team Inspection services WHO INSPECTION REPORT of the FPP manufacturer Part 1 Manufacturers details Company information Name of manufacturer Corporate address of manufacturer Contact person
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory. Uganda (NDQCL-NDA) Mulago Hill, P.O. Box 23096, Kampala, Uganda. NDA,
SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory Part
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments
More informationAnnex 4. Guidance on good manufacturing practices: inspection report. Background
Annex 4 Guidance on good manufacturing practices: inspection report Background The need for revision of the Guidance on good manufacturing practices: inspection report (World Health Organization (WHO)
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer Calyx Chemicals & Pharmaceuticals Ltd Unit:
More informationThe World Bank. Aide Memoire for use during GMP inspections
The World Bank e for use during GMP inspections The World Bank Procurement of Health Sector Goods Contact persons: 0 1. General information about the manufacturer Name of manufacturer Physical address
More informationUNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products
UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September
More informationSITE MASTER FILE For MHRA
ABC CO., LTD. For MHRA Prepared by Date Approved by Date Verified by Date Document No.: SMF, Version No: 01, Effective Date: 09/05/06 Document No.: SMF Version No.: 01 Effective Date: 09/05/06 Page 2 of
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer Shanghai Shyndec Pharmaceutical (Haimen)
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationSupersedes Division Name Revision No. 0 Export Division Page No. 1 of 9
Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1 General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1 Manufacturers details Company information Name of manufacturer Corporate address of
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory
SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory Part
More information18.H Questionnaire for preparing GMP-inspections
Questionnaire for preparing -inspections Questionnaire for preparing -inspections Here you will find answers to the following questions: What questions are typically asked during inspections based on current
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) of the API manufacturer. India
WHO PUBLIC INSPECTION REPORT (WHOPIR) of the API manufacturer Part 1: General information about the inspection Name of manufacturer IPCA Laboratories Ltd. Indore, India Physical address: Plot No 89A-B/90/91
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT API Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Part 1: General information Name of Manufacture Unit number
More informationTechnical updates medicines inspections: Finished Pharmaceutical Products (FPP)
Technical updates medicines inspections: Finished Pharmaceutical Products (FPP) Vimal Sachdeva, Technical Officer (Inspector) WHO Prequalification Team (PQT), WHO/HIS/EMP/RHT 20 Avenue Appia, CH - 1211,
More informationPrequalification Team Inspection services WHO INSPECTION REPORT of the FPP manufacturer
Part 1 Manufacturers Details Company information Name of manufacturer Corporate address of manufacturer Contact person Inspected site Address of inspected manufacturing site if different from that given
More informationPrequalification Team Inspection services WHO PUBLICK INSPECTION REPORT of the FPP manufacturer
Prequalification Team Inspection services WHO PUBLICK INSPECTION REPORT of the FPP manufacturer Part 1 General information Manufacturers details Company information Name of Anhui Biochem Bio-pharmaceutical
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part VIII of VIII Current article Part VIII Support QMS Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer
SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer
More informationV. S. International Pvt. Ltd
V. S. International Pvt. Ltd Innovation in medicine Partners In human care for today and tomorrow... Unit I - Daman V. S. International is a Healthcare Company with it s Corporate Head office at Mumbai,
More informationGMP Compliance. George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd
GMP Compliance George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd June 2017 Overview GMP Definition and Regulation Our Philosophy and Strategy for Compliance Project Lifecycle Deliverables Master
More informationSupplementary Training Modules on Good Manufacturing Practice. Validation. WHO Technical Report Series, No. 937, Annex 4.
Supplementary Training Modules on Good Manufacturing Practice Validation WHO Technical Report Series, No. 937, 2006. Annex 4. Validation Slide 1 of 48 August 2006 Validation! Part 1. General overview on
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationGMP & Quality Assurance. Mayur Sushir Dept of Microbiology MJC
GMP & Quality Assurance Mayur Sushir Dept of Microbiology MJC Introduction GMP ensures that quality is built into the organization & processes involved in manufacture GMP covers all aspects of manufacture
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationIntroduction to Medicines Inspections Technical Updates:
Introduction to Medicines Inspections Technical Updates: GMP inspections of Active Pharmaceutical Ingrédients and Finished Pharmaceutical Products (including Reproductive Health Products) Vimal Sachdeva,
More informationRegional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators
Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Focused on GMP in production of Active Pharmaceutical Ingredients and Oral Solid Dosage Forms Organized
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationPURITAN PRODUCTS QUALITY OVERVIEW. Quality Management System Self-Audit. September 15, 2015
PURITAN PRODUCTS QUALITY OVERVIEW Quality Management System Self-Audit September 15, 2015 Founded in 1987, Puritan Products, Inc. is a cgmp compliant, FDA registered and inspected, and ISO-9001:2008 certified
More informationGUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PH 1/97 (Rev. 3), 15 January 2002 ANNEX 15 QUALIFICATION AND
More informationAnnex 13 WHO guidelines for preparing a laboratory information file
World Health Organization WHO Technical Report Series, No. 961, 2011 Annex 13 WHO guidelines for preparing a laboratory information file Background The WHO Expert Committee on Specifications for Pharmaceutical
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationBrief Introduction of Aburaihan Company Organization Policy Organization Chart Qualified Human Resource Production Department Engineering Department
1 Contents Brief Introduction of Aburaihan Company Organization Policy Organization Chart Qualified Human Resource Production Department Engineering Department Sanitation and Environment Protection Documentation
More informationDr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur
Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient Manufacturer QILU TIANHE PHARMACEUTICAL CO.
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient Manufacturer Part 1 Manufacturers details Company information Name of manufacturer Corporate address of manufacturer
More informationRECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS
RECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS Facilities that manufacture 117, pack, or hold dietary supplements are subject to the regulations in 21 CFR Part 111, while those that manufacture, pack,
More informationLatino America Consultores Innovation & Technology to make your Business Compliant
Latino America Consultores Innovation & Technology to make your Business Compliant Annex 15 & EMA Process Validation Guide Line 1 Changes in Requirements The Pharmaceutical Industry has adapted its business
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part IV of VIII Current article Part IV Quality Systems Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General information
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General information Name of Manufacturer M/s. Hetero Labs Limited Unit number Production
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationGMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP)
GMP Requirements Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) 2016. ALL RIGHTS RESERVED. Outline GMP Procedures and standards
More informationGood manufacturing practices
ORIGINAL PAPER 1AR-10 ISBT Science Series (2009) 4, 6 10 Journal compilation 2009 International Society of Blood Transfusion Good manufacturing practices Blackwell Publishing Ltd A. Ahmed Quality Manager,
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, 6 February 2014 SANCO/TSE/ The received contributions together with the identity of
More informationSESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt
Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) of the FPP manufacturer
WHO PUBLIC INSPECTION REPORT (WHOPIR) of the FPP manufacturer Part 1: General information about the inspection Name of manufacturer Meditab Specialities Pvt. Ltd. Physical /postal address J-4/2 Additional
More informationThe procurement, qualification and calibration of lab instruments: An Overview
The procurement, qualification and calibration of lab instruments: An Overview The reliability of analytical data generated from chemical and physical analyses is critically dependent on three factors:
More informationName of Chapter & Details. Section-I
Course Title Course Code INTRODUCTION TO QA AND DOCUMENTATION QA1 Lecture : Course Credit Practical : 00 Tutorial : 00 Total : Course Objectives To explain the students about quality control, quality assurance,
More informationPrequalification Team Inspection services WHO INSPECTION REPORT of the Quality Control laboratory
Prequalification Team Inspection services WHO INSPECTION REPORT of the Quality Control laboratory Part 1 Laboratory details Laboratory information Name of the laboratory Corporate address of Laboratory
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationProcess development and basic GMP
Process development and basic GMP Aulton Chapter 45, handouts Specification, stability, inprocess controls and validation Product development Process development Critical Product Qualities issues Critical
More information3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API)
Title: Good Working Practice Validation Requirements Practice Number: 06 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Topics: 1. Biological Test Methods
More informationCONTACT US... Your Partner on the Path of...making a Healthier Mankind. Follow us. Scan for web.
CONTACT US... INDIA HEAD OFFICE 430, DLF TOWERS, SHIVAJI MARG NEW DELHI-110015 INDIA TEL +91 11 4932 1000 FAX +91 11 4932 1024 E-MAIL xlrem@vsnl.com admin@xllaboratories.com WEB PLANT-1 E-1223 PHASE-I
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer / Iksan Plant Unit number Production Block Physical address Contact person and email
More informationHISTORY AND MILESTONES
HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationPERFORMANCE QUALIFICATION PROTOCOL HVAC SYSTEM
Page 1 of 24 PERFORMANCE QUALIFICATION PROTOCOL FOR HVAC SYSTEM Signing of this Performance Qualification Protocol indicates agreement with the Validation Master Plan approach of the equipment. Further
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory
SOP 408 Annex D 20, AVENUE APPIA CH-1211 GENEVA 27 SWITZERLAND TEL CENTRAL +41 22 791 2111 FAX CENTRAL +41 22 791 3111 WWW.WHO.INT WHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory Part
More informationEudraLex. Part I1 Chapter 6: Quality Control
EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines tofor Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part I1 Chapter 6: Quality
More informationPROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT
August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline
More informationSUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION
Pharmapathway.com SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION Page 1 of 43 1. INTRODUCTION Validation is an essential and integral part of Good Manufacturing Practice (GMP).
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part III of VIII Current article Part III Production Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationHACCP audit checklist
Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex
More informationCOMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
More informationCRITICAL ASPECT ANALYTICAL TEST REVIEW
CRITICAL ASPECT ANALYTICAL TEST REVIEW Jakarta 14 December 2017 Speaker: HERU PURNOMO, ST QC WORK FLOW Start Sample Received (In-Process & Finished Good) Testing Review Lab Result Yes No Non Conformance
More informationRegulatory Expectations, Standards & Guidelines
Regulatory Expectations, Standards & Guidelines Regulatory Requirements Pharmacopeias Good Automated Manufacturing Practice (GAMP) 21 CFR Part 11 and Annex 11 Consequences of Non-Compliance 22 Regulatory
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationEffective Management and Operations of GXP Laboratories
Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice
More informationInternational Procurement and supply Schemes Part II
International Procurement and supply Schemes Part II by Dr. Nora Dellepiane Workshop: Global Registra8on and Vaccine Shortage Taipei, Taiwan 6 to 10 March 2017 Outline of the presentation Vaccine Supply
More informationQuestionnaire Layout:
Raw Material Supplier Questionnaire Introduction: This questionnaire has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations in developing
More informationTesto Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance
Testo Expert Knowledge The GxP Dictionary 1st edition Definitions relating to GxP and Quality Assurance Note: Some of the information contained in this GxP Dictionary does not apply equally to all countries.
More informationCalibration in the Laboratory
IVT Validation Week 2015 Calibration in the Laboratory 2015 The Lanese Group, Inc. Jerry Lanese Ph.D. The Lanese Group, Inc. 1 Outline Overview of laboratory data integrity Elements of the Laboratory Instrument
More informationINDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW
International Journal of Pharmacy Review & Research www.ijprr.com INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW Vishal Sharma* and Nimrata Seth 1 Department of Pharmaceutics, Rayat Institute
More informationAble Laboratories, Inc., Cranberry, NJ, FDA 483 Inspectional Observations, dated 05/02 07/01/2005
U.S. Food and Drug Administration Protecting and Promoting Your Health Able Laboratories, Inc., Cranberry, NJ, FDA 483 Inspectional Observations, dated 05/02 07/01/2005 Return to: Frequent/FOI Start (/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/default.htm)
More informationPIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 010-3 1 October 2008 PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
More informationData Integrity Compliance Project
Data Integrity Compliance Project RISK FACTORS FOR DI ISSUES Outsourcing Supply Chain Data Review Practices Increasing use of electronic systems Economic Stressors 2 Fully Integrated into QMS DATA INTEGRITY
More informationStrategies for Risk Based Validation of Laboratory Systems
Strategies for Risk Based Validation of Laboratory Systems Video Web Seminar September 23, 2004 Ludwig Huber E-mail: ludwig_huber@agilent.com Today s Agenda Background information: why risk assessment,
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer MSN Pharmachem Private Limited Unit Production
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.1 April 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationWHO GMP for Pharmaceutical Products: Main Principles
제약업계의품질경영 : 원칙과필수요소 (Quality management in the medicines industry: philosophy and essential elements) 1 In the medicines industry at large, quality management is usually defined as the aspect of the management
More informationGUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET
GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationPHARMACEUTICAL VALIDATION AND QUALITY MANAGEMENT SYSTEM
Course Title Course Code PHARMACEUTICAL VALIDATION AND QUALITY MANAGEMENT SYSTEM QA204 Lecture : 04 Course Credit Practical : 04 Tutorial : 00 Total : 08 Course Objective To explain the students about
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More information